EAACI Congress 2024
BackTPS05 - Asthma 2
Friday 31 May, 12:00 PM -
13:00 PM Valencia, Spain
Poster Zone
Thematic Poster Session
A 12 months real-life prospective study of lung function in patients with severe eosinophilic asthma undergoing therapy with ics/laba, lama, and anti IL5/5R monoclonal antibody
Asthma control, lung function, and quality of life in pediatric patients with severe asthma undergoing biological treatment
Benefits of the combination of biologics in the control of a patient with high type 2 profile: a case report
Dupilumab Efficacy in Allergic Bronchopulmonary Aspergillosis: a Case Report
Effectiveness of low dose mepolizumab in Korean eosinophilic granulomatosis with polyangiitis (EGPA) patients
Evaluation of the Pediatric Patients with Severe Eosinophilic Asthma Treated with Mepolizumab
Long-Term Efficacy of Mepolizumab at 5 Years in Patients with Severe Asthma
Safety of dupilumab in patients with severe asthma: real-life experience
Severe asthma in pediatrics and Dupilumab after failure with Omalizumab
Successful treatment of severe asthma after switch of biologics. A case report
Use of dupilumab in two pregnant women with nasal polyposis and severe persistent asthma: two case reports
Use of mepolizumab in a patient with early-onset and difficult-to-control asthma: A case report
VEXAS overlapping I-HES. A case report
Variables predicting clinical remission among adults with severe asthma treated with biologic agents
